Shilpa H

In-depth Quality Assurance (Documentation) Specialist with success in prioritization and multitasking. Exceptional communication and organizational skills. Committed to paying impeccable attention to reviews and auditing procedures. Willingness to take on added responsibilities to meet team goals.

Used SAP software to track the material receipt and clearance of stock for ordering, posting of materials and checking the goods receipt with invoice enty.

Have 3 Patents and >8 Publications in National and International Journals

Publications:  

1. Boliar S, Patil S, Shukla BN , Ghobeh A, Deshpande S, Chen W, Guenaga J, Dimitrov DS, Wyatt RT, Chakrabarti BK. Ligand accessibility to the HIV-1 Env co-receptor binding site can occur prior to CD4 engagement and is independent of viral tier category. Virology. 2018

2. Nandagopal P, Bhattacharya J, Srikrishnan AK, Goyal R, Ravichandran Swathirajan C, Patil S, Saravanan S, Deshpande S, Vignesh R, Solomon SS, Singla N, Mukherjee J, Murugavel KG. Broad neutralization response in a subset of HIV-1 subtype C-infected viraemic non-progressors from southern India. J Gen Virol. 2018 Feb 5. doi: 10.1099/jgv.0.001016.

3. Kumar R, Ozorowski G, Holden LG, Shrivastava T, Kumar V, Patil S, Sankhyan A, Deshpande S, Chakrabarti BK, Ward AB, Bhattacharya J. Characterization of a stable HIV-1 B/C recombinant, soluble, and trimeric envelope glycoprotein (Env) highly resistant to CD4-induced conformational changes. J Biol Chem. 2017 Sep 22; 292(38):15849-15858.

4. Deshpande S #; Patil S #; Kumar R; , Hermanus T, Murugavel KG, Srikrishnan AK, Solomon S, Morris L, Bhattacharya J. HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms. Retrovirology. 2016 Aug 30;13(1):60. [#Equal contribution]

5. Deshpande S#; Patil S#; Kumar R; Shrivastava T; Srikrishnan AK.; Murugavel KG.; Koff WC; Chakrabarti BK; Bhattacharya J. Association of mutations in V3/C3 domain with enhanced sensitivity of HIV-1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies. Retrovirology. 2016 Jun 15;13(1):41. doi: 10.1186/s12977-016-0273-x. [#Equal contribution]

6. Patil S, Kumar R, Deshpande S, Samal S, Shrivastava T, Boliar S, Bansal M, Chaudhary NK, Srikrishnan AK, Murugavel KG, Solomon S, Simek M, Koff WC, Goyal R, Chakrabarti BK, Bhattacharya J. Conformational epitope-specific broadly neutralizing plasma antibodies obtained from an HIV-1 Clade C infected elite neutralizer mediate autologous virus escape through mutations in V1 loop. J Virol. 2016 90: doi:10.1128/JVI.03090-15.

7. Boliar S, Das S, Bansal M, Shukla BN, Patil S, Shrivastava T, et al. An Efficiently Cleaved HIV-1 Clade C Env Selectively Binds to Neutralizing Antibodies. PLoS ONE. 2015 Mar 30; 10(3): e0122443. doi:10.1371/ journal.pone.0122443.

8. Patil S, Choudhary I, Chaudhary NK, Ringe R, Bansal M, Shukla BN, Boliar S, Chakrabarti BK, Bhattacharya J. Determinants in V2C2 region of HIV-1 clade C primary envelopes conferred altered neutralization susceptibilities to IgG1b12 and PG9 monoclonal antibodies in a context-dependent manner. Virology. 2014 Aug, 462-463:266-72.

Patents:

1. Nucleotide sequence encoding HIV 1 Clade C envelope protein and use of its expression product in immunological composition against HIV 1 infection. Inventors: Jayanta Bhattacharya, Suprit Deshpande, Shilpa Patil, Rajesh Kumar, Murugavel Kailapuri Gangatharan. Details of Journal: Official Journal of the Patent Office, Issue No:04/2018, Date of Publication: 26/01/2018.

2. Engineered Recombinant Protein Antigen of Trimeric Mimic of HIV-1 Glycoprotein Envelope Spike. US Provisional Application being filed by IAVI, Ref: 43094.00.2042, 2016 (Jayanta Bhattacharya (PI), Rajesh Kumar, Vivek Kumar Yadav, Shilpa Patil).

3. HIV-1 CLADE ENVELOPE GLYCOPROTEINS: US Provisional Application 62/254,971filed by IAVI on 13th Nov, 2015 (Docket No. 43094.01.2038). (Jayanta Bhattacharya, (PI), Suprit Deshpande, Shilpa Patil, Rajesh Kumar, Bimal K. Chakrabarti).